Matritech deal

Boehringer Ingelheim International GmbH received semi-exclusive rights to distribute the Cambridge, Mass., company's cancer diagnostic test kits and research reagents. Boehringer acquired 400,000 NMPS shares for $1 million and paid $1 million for the European marketing rights. NMPS will receive a second $1 million payment shortly upon delivery of certain technical data to Boehringer. Boehringer has right of first refusal to marketing rights for other products in exchange for the purchase of additional equity at a premium to the market price. ...